People with Type 1 diabetes in England and Wales are set to benefit from groundbreaking technology that could transform their daily lives, following a landmark decision by the National Institute for Health and Care Excellence (NICE). The health watchdog has recommended that hybrid closed-loop systems – often called 'artificial pancreas' devices – should be made available on the NHS to thousands of patients who meet specific criteria.
These sophisticated systems work by connecting a continuous glucose monitor to an insulin pump, with clever algorithms automatically adjusting insulin delivery based on real-time blood sugar readings. For people living with Type 1 diabetes, this means significantly fewer finger-prick tests and manual insulin adjustments – reducing the relentless daily burden of managing their condition whilst helping prevent dangerous episodes of very high or low blood sugar.
The NHS will prioritise access for those who need it most. All children and young people with Type 1 diabetes will be eligible for the systems, alongside adults who are pregnant or planning pregnancy. Adults with an HbA1c level of 7.5% or higher – indicating suboptimal blood sugar control – or those experiencing repeated severe low blood sugar episodes will also receive priority access. This phased approach ensures the technology reaches those who stand to benefit most immediately.
NICE's decision follows rigorous evaluation of both clinical effectiveness and cost-effectiveness. Diabetes UK, the leading diabetes charity, has campaigned tirelessly for wider access to this technology, emphasising its life-changing potential. The charity estimates tens of thousands of people could eventually benefit, experiencing greater freedom and less anxiety in managing their diabetes day-to-day.
Local NHS integrated care boards will now work to procure and roll out these systems across their areas. Whilst implementation will be gradual, this represents a significant leap forward in diabetes care – bringing cutting-edge treatment to a much broader population and helping improve long-term health outcomes for people with Type 1 diabetes across the UK.